Journals / Türk Oftalmoloji Dergisi / 2016 / Cilt: 46 - Sayı: 2

Herpetic Keratouveitis and Trabeculectomy Failure during Infliximab Therapy in a Patient with Behçet's Disease

İnfliksimab Tedavisi Altındaki Bir Behçet Hastasında Gelişen Herpetik Keratoüveit ve Trabekülektomi Yetmezliği

Pages
87–90
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Trabeculectomy with mitomycin C was performed about halfway through an eight-week interval between two doses of infliximab

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 51-year-old man was diagnosed with Behçet's disease in 2001.
📊
Key Findings & Data:After 6 months of infliximab therapy, he presented to our clinic with pain and blurred vision in his right eye.
💡
Conclusion & Impact:Trabeculectomy with mitomycin C was performed about halfway through an eight-week interval between two doses of infliximab
🔬Design:Research Article
📍Scope:2001 Verileri
⚙️Variables:Domain Parameters

Abstract

A 51-year-old man was diagnosed with Behçet's disease in 2001. The patient was resistant to all immunosuppressive therapies. After 6 months of infliximab therapy, he presented to our clinic with pain and blurred vision in his right eye. The visual acuity was 20/200 and the intraocular pressure was 35 mmHg in the right eye. Biomicroscopic examination revealed corneal dendritic ulcers and 2+ cells in the anterior chamber in the right eye. The herpetic keratouveitis attack was controlled with antiviral therapy but the patient needed another glaucoma surgery. Trabeculectomy with mitomycin C was performed about halfway through an eight-week interval between two doses of infliximab

Özet

Elli bir yaşında erkek hastaya 2001 yılında Behçet hastalığı tanısı konuldu. Hasta tüm immünsüpresif tedavilere dirençliydi. Altı aylık infliksimab tedavisinin ardından kliniğimize sağ gözünde ağrı ve bulanık görme ile başvurdu. Görme keskinliği sağ gözde 20/200'dü ve göz içi basıncı 35 mmHg idi. Biyomikroskopik muayenesinde korneada dendritik ülserleri ve ön kamarada 2+ hücresi mevcuttu. Herpetik keratoüveit atakları antiviral tedavi ile kontrol altına alındı ancak hastanın yeniden glokom ameliyatı olması gerekti. İki infliksimab tedavisinin arasındaki sekiz haftalık sürecin ortasında hastaya mitomisin C'li trabekülektomi ameliyatı yapıldı

🔖

Cite This Article

ASENA, L., GÖKMEN, O., GÜNGÖR, S. G., AKMAN, A. (2022). Herpetic Keratouveitis and Trabeculectomy Failure during Infliximab Therapy in a Patient with Behçet's Disease. Türk Oftalmoloji Dergisi, Cilt: 46 - Sayı: 2, 87–90. https://ajindex.com/articles/637896

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001;358:295-296.
  2. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-1368.
  3. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003;48:3013-3022.
  4. Sakai T, Kanetaka A, Noro T, Tsuneoka H. Intraocular surgery in patients receiving infliximab therapy for Behçet disease. Jpn J Ophthalmol. 2010;54:360-361.
  5. Yalvac IS, Sungur G, Turhan E, Eksioglu U, Duman S. Trabeculectomy with mitomycin-C in uveitic glaucoma associated with Behçet disease. J Glaucoma. 2004;13:450-453.
  6. Elgin U, Berker N, Batman A, Soykan E. Trabeculectomy with mitomycin C in secondary glaucoma associated with Behçet disease. J Glaucoma. 2007;16:68-72.
  7. Nishida T, Shibuya E, Asukata Y, Nakamura S, Ishihara M, Hayashi K, Takeno M, Ishigatsubo Y, Mizuki N. Clinical course before and after cataract and glaucoma surgery under systemic infliximab therapy in patients with Behçet's disease. Case Report Ophthalmol. 2011;2:189-192.
  8. Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Risk of herpes zoster in psoriatic patients undergoing biologic treatment. J Dermatol. 2014;41:168- 170. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57:1431- 1438. Dreiher J, Kresch FS, Comaneshter D, Cohen AD. Risk of Herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol. 2012;26:1127-1132.
  9. Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti- tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014;81:215-221.
  10. Cruz MJ, Baudrier T, Ferreira O, Azevedo F. Herpes zoster at the site of infliximab infusion: case report. Cutan Ocul Toxicol. 2011;30:236-238.
  11. Wang X, Zhao J, Zhu S, Xia B. Herpes zoster in Crohn's disease during treatment with infliximab. Eur J Gastroenterol Hepatol. 2014;26:237-239.
  12. Sciaudone G, Pellino G, Guadagni I, Selvaggi F. Education and imaging: gastrointestinal: herpes simplex virus-associated er